Renal Cancer - Results from #1660

Risk of recurrence after nephrectomy: Comparison of predictive ability of validated risk models. January 19, 2022

Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review. January 19, 2022

Risk-group Classification by Recursive Partitioning Analysis of Patients Affected by Oligometastatic Renal Cancer Treated with Stereotactic Radiotherapy. January 18, 2022

Surgical outcomes for older patients with renal cell carcinoma and inferior vena cava thrombus. January 18, 2022

Thermal Ablation Combined with Selective Transarterial Embolization of Centrally Located Renal Cell Carcinomas Measuring 3 cm or Larger. January 17, 2022

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. January 17, 2022

Parenchymal Mass Loss During Partial Nephrectomy: Role of Devascularized Parenchymal Mass and Excised Parenchymal Mass and Impact on Functional Preservation. January 14, 2022

Prognostic Significance of NLR About NETosis and Lymphocytes Perturbations in Localized Renal Cell Carcinoma With Tumor Thrombus. January 14, 2022

cMET - a prognostic marker in papillary renal cell carcinoma? January 13, 2022

Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma. January 13, 2022

A 17-Gene Expression Signature for Early Identification of Poor Prognosis in Clear Cell Renal Cell Carcinoma. January 13, 2022

Short-Term and Long-Term Renal Outcomes in Patients With Obesity After Minimally Invasive Versus Open Partial Nephrectomy for the Treatment of Renal Cancer: Retrospective Study. January 12, 2022

The renal clear cell carcinoma immune landscape. January 12, 2022

Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. January 11, 2022

Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma. January 11, 2022

Disparities in Cancer Specific and Overall Survival Outcomes in African Americans with Renal Cell Carcinoma: Analysis from the International Marker Consortium for Renal Cancer (INMARC). January 10, 2022

Risk factors for recurrence after operation in patients with pT1a renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association. January 10, 2022

Identification of adhesion-associated extracellular matrix component thrombospondin 3 as a prognostic signature for clear cell renal cell carcinoma. January 7, 2022

Integrative clinical and molecular characterization of translocation renal cell carcinoma. January 7, 2022

Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study. January 6, 2022

Page 84 of 456